{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:36:38Z","timestamp":1790872598146,"version":"4.1.0"},"reference-count":24,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2007,10,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> This study was undertaken to assess if prolonged paclitaxel administration in combination with cisplatin improves overall survival (OS) in epithelial ovarian cancer (EOC). <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Eligible patients with suboptimal stage III or IV EOC, fallopian tube, or primary peritoneal cancer were randomly allocated to receive six cycles of cisplatin 75 mg\/m<jats:sup>2<\/jats:sup> and either paclitaxel 135 mg\/m<jats:sup>2<\/jats:sup> during 24 hours (arm 1) or paclitaxel 120 mg\/m<jats:sup>2<\/jats:sup> during 96 hours (arm 2). <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Planned accrual was 324 patients; 293 were enrolled before the study was closed as a result of a scheduled interim futility analysis. There were 13 ineligible patients; thus, 140 patients in each arm were assessable. In arm 1, 80% of patients completed all six cycles compared with 83% of patients in arm 2. Grade 4 granulocytopenia was more common in arm 1 (79% v 54%; P &lt; .001) whereas grade 3 or worse anemia was more severe in arm 2 (6% v 18%; P &lt; .003). The median progression-free survival was 1.03 years for arm 1 versus 1.05 years for arm 2. The median OS was 2.49 and 2.54 years for arms 1 and 2, respectively. There have been 237 reported deaths. The relative death rate was approximately 12% greater in arm 2 (hazard ratio, 1.12; 95% CI, 0.860 to 1.45). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Patients with advanced EOC have a relatively poor prognosis. The results of treatment with cisplatin and paclitaxel are not significantly improved by prolonging the paclitaxel infusion from 24 to 96 hours. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2006.10.3846","type":"journal-article","created":{"date-parts":[[2007,9,28]],"date-time":"2007-09-28T22:26:30Z","timestamp":1191018390000},"page":"4466-4471","source":"Crossref","is-referenced-by-count":51,"title":["Phase III Randomized Trial of Intravenous Cisplatin Plus a 24- or 96-Hour Infusion of Paclitaxel in Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study"],"prefix":"10.1200","volume":"25","author":[{"given":"David R.","family":"Spriggs","sequence":"first","affiliation":[{"name":"From the Division of Solid Tumor Oncology, Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York; Gynecologic Oncology Group Statistical & Data Center, Roswell Park Cancer Institute, Buffalo, NY; Gynecologic Oncology and Pelvic Surgery Associates, Mount Carmel Health Center, Columbus, OH; Division of Gynecologic Oncology, University of North Carolina School of Medicine, Chapel Hill, NC; Department of Clinical Obstetrics & Gynecology, Division of Gynecologic Oncology, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark F.","family":"Brady","sequence":"additional","affiliation":[{"name":"From the Division of Solid Tumor Oncology, Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York; Gynecologic Oncology Group Statistical & Data Center, Roswell Park Cancer Institute, Buffalo, NY; Gynecologic Oncology and Pelvic Surgery Associates, Mount Carmel Health Center, Columbus, OH; Division of Gynecologic Oncology, University of North Carolina School of Medicine, Chapel Hill, NC; Department of Clinical Obstetrics & Gynecology, Division of Gynecologic Oncology, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Vaccarello","sequence":"additional","affiliation":[{"name":"From the Division of Solid Tumor Oncology, Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York; Gynecologic Oncology Group Statistical & Data Center, Roswell Park Cancer Institute, Buffalo, NY; Gynecologic Oncology and Pelvic Surgery Associates, Mount Carmel Health Center, Columbus, OH; Division of Gynecologic Oncology, University of North Carolina School of Medicine, Chapel Hill, NC; Department of Clinical Obstetrics & Gynecology, Division of Gynecologic Oncology, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Clarke-Pearson","sequence":"additional","affiliation":[{"name":"From the Division of Solid Tumor Oncology, Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York; Gynecologic Oncology Group Statistical & Data Center, Roswell Park Cancer Institute, Buffalo, NY; Gynecologic Oncology and Pelvic Surgery Associates, Mount Carmel Health Center, Columbus, OH; Division of Gynecologic Oncology, University of North Carolina School of Medicine, Chapel Hill, NC; Department of Clinical Obstetrics & Gynecology, Division of Gynecologic Oncology, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Burger","sequence":"additional","affiliation":[{"name":"From the Division of Solid Tumor Oncology, Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York; Gynecologic Oncology Group Statistical & Data Center, Roswell Park Cancer Institute, Buffalo, NY; Gynecologic Oncology and Pelvic Surgery Associates, Mount Carmel Health Center, Columbus, OH; Division of Gynecologic Oncology, University of North Carolina School of Medicine, Chapel Hill, NC; Department of Clinical Obstetrics & Gynecology, Division of Gynecologic Oncology, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Mannel","sequence":"additional","affiliation":[{"name":"From the Division of Solid Tumor Oncology, Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York; Gynecologic Oncology Group Statistical & Data Center, Roswell Park Cancer Institute, Buffalo, NY; Gynecologic Oncology and Pelvic Surgery Associates, Mount Carmel Health Center, Columbus, OH; Division of Gynecologic Oncology, University of North Carolina School of Medicine, Chapel Hill, NC; Department of Clinical Obstetrics & Gynecology, Division of Gynecologic Oncology, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Boggess","sequence":"additional","affiliation":[{"name":"From the Division of Solid Tumor Oncology, Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York; Gynecologic Oncology Group Statistical & Data Center, Roswell Park Cancer Institute, Buffalo, NY; Gynecologic Oncology and Pelvic Surgery Associates, Mount Carmel Health Center, Columbus, OH; Division of Gynecologic Oncology, University of North Carolina School of Medicine, Chapel Hill, NC; Department of Clinical Obstetrics & Gynecology, Division of Gynecologic Oncology, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger B.","family":"Lee","sequence":"additional","affiliation":[{"name":"From the Division of Solid Tumor Oncology, Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York; Gynecologic Oncology Group Statistical & Data Center, Roswell Park Cancer Institute, Buffalo, NY; Gynecologic Oncology and Pelvic Surgery Associates, Mount Carmel Health Center, Columbus, OH; Division of Gynecologic Oncology, University of North Carolina School of Medicine, Chapel Hill, NC; Department of Clinical Obstetrics & Gynecology, Division of Gynecologic Oncology, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hanly","sequence":"additional","affiliation":[{"name":"From the Division of Solid Tumor Oncology, Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York; Gynecologic Oncology Group Statistical & Data Center, Roswell Park Cancer Institute, Buffalo, NY; Gynecologic Oncology and Pelvic Surgery Associates, Mount Carmel Health Center, Columbus, OH; Division of Gynecologic Oncology, University of North Carolina School of Medicine, Chapel Hill, NC; Department of Clinical Obstetrics & Gynecology, Division of Gynecologic Oncology, University..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199601043340101"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.9.699"},{"key":"R3","unstructured":"Kearns CM, Gianni L, Egorin MJ: Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 22(3 suppl 6):16,1995-23,"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.1.180"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.12.2654"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.082"},{"key":"R7","unstructured":"Donehower RC, Rowinsky EK, Grochow LB, et al: Phase I trial of Taxol in patients with advanced cancer. Cancer Treat Rep 71:1171,1987-1177,"},{"key":"R8","unstructured":"Schiller JH, Storer B, Tutsch K, et al: A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor. Semin Oncol 21(5 suppl 8):9,1994-14,"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-111-4-273"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1007\/BF00944181"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.187"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.6.1877"},{"key":"R13","unstructured":"Abu-Rustum NR, Aghajanian C, Barakat RR, et al: Salvage weekly paclitaxel in recurrent ovarian cancer. Semin Oncol 24(5 suppl 15):S15-62,1997-S15-67,"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.735"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041125"},{"key":"R16","unstructured":"Blessing JA: Design, analysis and interpretation of chemotherapy trials in gynecology cancer, in Deppe G (ed): Chemotherapy of Gynecology Cancer (ed 2) . New York, NY, Alan R Liss, pp 63,1990-97"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.2307\/2531021"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc A 35:185,1972-206,","DOI":"10.2307\/2344317"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.2307\/2530245"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.8.1621"},{"key":"R22","unstructured":"Breathnach OS, Georgiadis MS, Schuler BS, et al: Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer. Clin Cancer Res 6:2670,2000-2676,"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.1.106"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09738-6"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2006.10.3846","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:10:47Z","timestamp":1653509447000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2006.10.3846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,1]]},"references-count":24,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2007,10,1]]}},"alternative-id":["10.1200\/JCO.2006.10.3846"],"URL":"https:\/\/doi.org\/10.1200\/jco.2006.10.3846","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,1]]}}}